Abstract
BackgroundWorldwide, methotrexate (MTX) is considered the first-line disease-modifying antirheumatic drug treatment for patients with rheumatoid arthritis (RA). MTX compliance among patients with RA may be influenced by MTX response, adverse...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have